Skip to main content
HR 3616 109th Congress House Health Agriculture and Food Animals Child health Clinical trials Colon cancer Congress Congressional reporting requirements Demography Digestive diseases Economics and Public Finance Education Environmental Protection Environmentally induced diseases Epidemiology Families Federal aid to research Genetic research Genetics Health education

Inflammatory Bowel Disease Research Act

Introduced: July 29, 2005 See on congress.gov
 Everywhere this bill has been 4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Nov 10, 2005
Sponsor introductory remarks on measure. (CR E2334)
Aug 5, 2005
Referred to the Subcommittee on Health.
Jul 29, 2005
Referred to the House Committee on Energy and Commerce.
Jul 29, 2005
Introduced in House
 Plain-English summary Congressional Research Service

Inflammatory Bowel Disease Research Act - Requires the Director of the National Institute of Diabetes and Digestive and Kidney Diseases to expand, intensify, and coordinate the Institute's research activities on inflammatory bowel disease, with an emphasis on: (1) genetic research on susceptibility for inflammatory bowel disease; (2) research targeted to increase knowledge about the causes and complications of inflammatory bowel disease in children; (3) animal model research; (4) clinical research; (5) expansion of the Institute's Inflammatory Bowel Disease Centers program with a focus on pediatric research; and (6) other research initiatives identified in specified documents.

Requires the Director of the Centers for Disease Control and Prevention (CDC) to prepare a National Inflammatory Bowel Disease Action Plan to: (1) address the burden of inflammatory bowel disease in both adult and pediatric populations; (2) address strategies for determining the prevalence of the disease in the United States and the unique demographic characteristics of the patient community; (3) focus on strategies for increasing awareness about the disease within the general public and the health care community; and (4) address mechanisms designed to prevent the progression of the disease and the development of complications.

What's happening now November 10, 2005

Sponsor introductory remarks on measure. (CR E2334)

 Committees of jurisdiction 2